Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report) shares crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.07 and traded as high as $0.0792. Mateon Therapeutics shares last traded at $0.0792, with a volume of 12,541 shares changing hands.
Mateon Therapeutics Stock Performance
The company’s 50-day moving average price is $0.09 and its 200 day moving average price is $0.07. The stock has a market capitalization of $6.97 million, a PE ratio of -3.86 and a beta of 1.33.
About Mateon Therapeutics
Mateon Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision oncology therapies that selectively target tumor tissue. The company’s platform leverages tumor-activated peptides designed to bind to the fibrin–fibronectin complexes uniquely present in solid tumors, with the goal of improving the therapeutic index of cytotoxic payloads while limiting off-target effects.
Its lead asset, MH1, is a peptide–drug conjugate in Phase I clinical trials for advanced solid tumors.
Further Reading
- Five stocks we like better than Mateon Therapeutics
- Do not delete, read immediately
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- A U.S. “birthright” claim worth trillions – activated quietly
- The Crash Has Already Started (Most Just Don’t See It Yet)
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
